Pharmaceutisch Weekblad

, Volume 5, Issue 1, pp 22–27 | Cite as

Plasma levels of acetylsalicylic acid and salicylic acid after oral ingestion of plain and buffered acetylsalicylic acid in relation to bleeding time and thrombocyte function

  • J. H. Proost
  • G. W. Van Imhoff
  • H. Wesseling
Original Articles


Buffered acetylsafícylic acid (Alka Seltzer®,b-asa) and plain aspirin (p-asa) tablets were compared as to their effects on bleeding time and platelet function in eight healthy male volunteers. Two doses (500 and 1000 mg) of each preparation were investigated in a cross-over design, each volunteer being his own control in each dose group (n=4). Both preparations disturbed platelet aggregation to the same extent. Bleeding time increased after both preparations, though significantly more after the buffered preparation than after plain acetylsalicylic acid, irrespective of the dosage. The 1000 mg dose prolonged bleeding time significantly more than the 500 mg dose, irrespective of the preparation.

Kinetic analysis showed thatb-asa gave higher peak plasma levels of acetylsalicylic acid (asa) and accordingly salicylic acid peak levels were also higher after the buffered preparation.

It is concluded thatb-asa in equi-analgesic doses prolongs bleeding time more than the plain preparation. Since it is less agressive on the gastro-intestinal mucosa, its use may be advantageous in situations where acetylsalicylic acid induced loss of platelet aggregation is desired.

However, the risk of prolonged bleeding —e.g. after tooth extractions — is probably higher after the buffered preparation.


Aspirin Salicylic Acid Platelet Aggregation Platelet Function Acetylsalicylic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Born, G.V.R. (1962)Nature 194, 927–929.Google Scholar
  2. Bowen, K.B., W.J. Krause enK.J. Ivey (1977)Br. Med. J. 6094, 1052–1055.Google Scholar
  3. Ivy, A.C., D. Nelson enG. Bucher (1941)J. Lab. Clin. Med. 26, 1812–1822.Google Scholar
  4. Jørgensen, K.A., J. Dyerberg, A.S. Olesen enE. Stoffersen (1980)Thromb. Res. 19, 799–805.Google Scholar
  5. Mason, W.D., enN. Winer (1981)J. Pharm. Sci. 70, 262–265.Google Scholar
  6. Moolenaar, F., N.J.J. Oldenhof, W. Groenewoud enT. Huizinga (1979)Pharm. Weekbl. [Sci.]2, 243–253.Google Scholar
  7. Morgan, K.T., F. Duchosal, C. Rogg enP.A. Miesker (1980)Acta Haemat. 63, 177–184.Google Scholar
  8. O'brien, J.R. (1968)Lancet I, 779–783.Google Scholar
  9. O'grady, J., enS. Moncada (1978)Lancet I, 780.Google Scholar
  10. Rauws, A.G. (1983) Rijksinstituut voor de Volksgezondheid, Bilthoven, The Netherlands, in press.Google Scholar
  11. Rothschild, B.M. (1979)Clin. Pharmacol. Ther. 26, 145–152.Google Scholar
  12. Stubbé, L.Th.F.L., J.H. Pietersen enC. Van Heulen (1962)Br. Med. J. 5279, 675–680.Google Scholar
  13. Van Ginneken, Ca.M. (1976) Ph.D. Thesis, Nijmegen, The Netherlands.Google Scholar
  14. Wood, P.H., E.A. Harvey-Smith enA.S.J. Dixon (1962)Br. Med. J. 5279, 669–675.Google Scholar
  15. Zdrakovic, M., G. Thomsen Pedersen, N.A. Klitgaard enE. Rasmussen (1981)Arch. Pharm. Chem., Sci. Ed. 9, 25–33.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1983

Authors and Affiliations

  • J. H. Proost
    • 1
  • G. W. Van Imhoff
    • 2
  • H. Wesseling
    • 3
  1. 1.Laboratory for Pharmaceutical Technology and DispensingState UniversityAW GroningenThe Netherlands
  2. 2.Division of Haematology, Department of Internal MedicineUniversity HospitalRB GroningenThe Netherlands
  3. 3.Institute for Clinical PharmacologyState UniversityBZ GroningenThe Netherlands

Personalised recommendations